Epidemiology
- USA: 240K diagnosed per yea
- USA: 30K die of prostate cancer
Prognosis
- Patients who undergo definitive treatment with a radical prostatectomy typically are quoted 5 and 10 year biochemical progression free survival (PFS) rates of 80% and 68%, respectively.
- Radiotherapy, consisting of either external beam radiation therapy or brachytherapy, can also be utilized for definitive therapy of clinically localized prostate cancer, with a 10-year biochemical PFS of 50 — 70%.
- Despite high cure rates with definitive therapy, approximately 35% of patients will still experience a biochemical recurrence within 10 years of receiving treatment. Among patients who develop biochemical recurrence, approximately one-third will develop radiographic evidence of metastatic disease within 8 years from the time of PSA elevation.
Among patients who develop biochemical recurrence, approximately one-third will develop radiographic evidence of metastatic disease within 8 years from the time of PSA elevation.
